Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response correctly identifies that REMICADE label sections 5.1 (Serious Infections) and 5.2 (Malignancies) support the claim, with no contradictions and no apparent missing material information relative to the narrow claim.
Category Scores
Accurate Statements
Patients treated with REMICADE are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
Supported by Warnings and Precautions 5.1 (Serious Infections)
Treatment with REMICADE should not be initiated in patients with an active infection (including clinically important localized infections).
Supported by Warnings and Precautions 5.1 (Serious Infections)
REMICADE should be discontinued if a patient develops a serious infection or sepsis.
Supported by Warnings and Precautions 5.1 (Serious Infections)
Patients should be closely monitored for signs and symptoms of infection during and after treatment, including tuberculosis.
Supported by Warnings and Precautions 5.1 (Serious Infections) and Monitoring language within that section
Malignancies, some fatal, have been reported among children, adolescents and young adults who received treatment with TNF blockers including REMICADE.
Supported by Warnings and Precautions 5.2 (Malignancies)
Lymphomas (including Hodgkin's and non-Hodgkin's) have been reported; postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported with fatal outcomes.
Supported by Warnings and Precautions 5.2 (Malignancies), including Lymphomas and HSTCL subsections
Melanoma and Merkel cell carcinoma have been reported with TNF blocker therapy including REMICADE.
Supported by Warnings and Precautions 5.2 (Malignancies), Skin Cancer subsection
In controlled trials, more REMICADE-treated patients developed malignancies than placebo-treated patients.
Supported by Adverse Reactions 6.1 (Clinical Trials Experience) malignancy statement
Unsupported Statements
Contradictions
Important Omissions
The assessment does not explicitly mention that there is a boxed warning content related to malignancy risk in the label (though it is not clearly a factual claim in the AI response content beyond noting coverage of malignancy risk).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response stays within the narrow label-supported themes (serious infections and malignancy) and does not introduce dosing, contraindications, or management instructions beyond what is supported by the label excerpts cited.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission/under-specification: explicit boxed-warning identification was not included in the evaluated claim-citations.
Suggested Improvement
Explicitly cite the boxed-warning/prescribing-information boxed section (if required by the audit standard) alongside 5.2 when discussing malignancy risk, while keeping the rest of the assessment unchanged.